Evidence map›Paper›PMID 35079629›Full record

ArticleBioengineering & translational medicine2022

Transplantation of patient-specific bile duct bioengineered with chemically reprogrammed and microtopographically differentiated cells.

Elina Maria Buisson, Suk-Hee Park, Myounghoi Kim, Kyojin Kang, Sangtae Yoon, Ji Eun Lee, Young Won Kim, Nak Kyu Lee, Mi Ae Jeong, Bo-Kyeong Kang and 7 more

Open access · goldAbstract read
In one paragraph

Article in Bioengineering & translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Bioengineered Bile Duct for Liver Regenerative Medicine and Bile Duct Reconstruction.JGH open : an open access journal of gastroenterology and hepatology · 2025
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

Elina Maria BuissonDepartment of Surgery Hanyang University College of Medicine Seoul Republic of Korea.
Suk-Hee ParkSchool of Mechanical Engineering Pusan National University Busan Republic of Korea.
Myounghoi KimDepartment of Surgery Hanyang University College of Medicine Seoul Republic of Korea.
Kyojin KangDepartment of Surgery Hanyang University College of Medicine Seoul Republic of Korea.
Sangtae YoonDepartment of Surgery Hanyang University College of Medicine Seoul Republic of Korea.
Ji Eun LeeDigital Manufacturing Process Group Korea Institute of Industrial Technology Siheungsi Gyeonggi-do Republic of Korea.
Young Won KimDigital Manufacturing Process Group Korea Institute of Industrial Technology Siheungsi Gyeonggi-do Republic of Korea.
Nak Kyu LeeDigital Manufacturing Process Group Korea Institute of Industrial Technology Siheungsi Gyeonggi-do Republic of Korea.
Mi Ae JeongDepartment of Anesthesiology and pain medicine Hanyang University College of Medicine Seoul Republic of Korea.
Bo-Kyeong KangDepartment of Radiology Hanyang University, College of medicine Seoul Republic of Korea.
Seung Bum LeeLaboratory of Radiation Exposure & Therapeutics National Radiation Emergency Medical Center, Korea Institute of Radiological & Medical Science Seoul Republic of Korea.
Valentina M FactorLaboratory of Molecular Pharmacology Center for Cancer Research, National Cancer Institute, National Institutes of Health Bethesda Maryland USA.
Daekwan SeoPsomagen Inc Rockville Maryland USA.
Hyunsung KimDepartment of Pathology Hanyang University College of Medicine Seoul Republic of Korea.
Jaemin JeongDepartment of Surgery Hanyang University College of Medicine Seoul Republic of Korea.ORCID https://orcid.org/0000-0001-9758-7917
Han Joon KimDepartment of Surgery Hanyang University College of Medicine Seoul Republic of Korea.
Dongho ChoiDepartment of Surgery Hanyang University College of Medicine Seoul Republic of Korea.
Hanyang University Medical Center · KRKorea Institute of Industrial Technology · KRHanyang University · KRKorea Institute of Radiological and Medical Sciences · KRMacroGenics (United States) · USNational Institutes of Health · USPusan National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholangiopathy is a diverse spectrum of chronic progressive bile duct disorders with limited treatment options and dismal outcomes. Scaffold- and stem cell-based tissue engineering technologies hold great promise for reconstructive surgery and tissue repair. Here, we report a combined application of 3D scaffold fabrication and reprogramming of patient-specific human hepatocytes to produce implantable artificial tissues that imitate the mechanical and biological properties of native bile ducts. The human chemically derived hepatic progenitor cells (hCdHs) were generated using two small molecules A83-01 and CHIR99021 and seeded inside the tubular scaffold engineered as a synergistic combination of two layers. The inner electrospun fibrous layer was made of nanoscale-macroscale polycaprolactone fibers acting to promote the hCdHs attachment and differentiation, while the outer microporous foam layer served to increase mechanical stability. The two layers of fiber and foam were fused robustly together thus creating coordinated mechanical flexibility to exclude any possible breaking during surgery. The gene expression profiling and histochemical assessment confirmed that hCdHs acquired the biliary epithelial phenotype and filled the entire surface of the fibrous matrix after 2 weeks of growth in the cholangiocyte differentiation medium in vitro. The fabricated construct replaced the macroscopic part of the common bile duct (CBD) and re-stored the bile flow in a rabbit model of acute CBD injury. Animals that received the acellular scaffolds did not survive after the replacement surgery. Thus, the artificial bile duct constructs populated with patient-specific hepatic progenitor cells could provide a scalable and compatible platform for treating bile duct diseases.

Indexed as

3D printingchemically derived hepatic progenitorscholangiocyteselectrospun fiberspatient‐specific bile duct

Identifiers

PMID35079629
PMCPMC8780056
OpenAlexW3196869859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.